第二届广州核酸国际论坛 议程盛大公布
主题：Nucleic Acids Translational Research & Therapeutics (siRNA, miRNA, lncRNA, antisense, CRISPR)
第二届广州核酸国际论坛（CNAF）以核酸转化研究与治疗为主题，旨在推动核酸研究和治疗药物的发展，加强中国与国际的交流合作，促进中国核酸生物产业的进步，展望核酸技术作为创新药物第三大发展引擎的美好前景。
本届论坛特邀20多位国际顶级科学家和企业家参会演讲，嘉宾囊括诺贝尔奖得主、世界百强药企的高级主管、世界顶级学府的著名教授、核酸制药上市公司的总裁、核酸治疗世界联盟主席等，内容涵盖RNAi、microRNA、lncRNA、antisense、mRNA、exon-skipping、CRISPR等核酸技术最新进展，包括从核酸基础研究到产业化，从临床前开发到临床研究，并分享去年世界首个核酸药物成功上市的经验。论坛的召开，将为国内科学家及研究生提供与本领域学术权威面对面交流的难得机会，为国内从事生物制药的企业单位提供与世界知名药企建立合作的纽带。
我们期待与您相聚美丽羊城，共同迎接核酸治疗时代的来临！
主办单位：专家联谊会生物医药和生命科学专业委员会
中国生化与分子生物学会核糖核酸专业委员会
中国科学院广州生物医药与健康研究院
呼吸疾病国家重点实验室
中山大学
承办单位：广州市锐博生物科技有限公司
开幕主旨演讲
Craig Mello教授
美国麻省大学医学院教授
2006年诺贝尔生理学或医学奖获得者
主旨演讲
 |
 |
 |
 |
|
Troels Koch博士
丹麦Santaris / Roche制药公司首席技术官，研发副总裁
|
Ekkehard Leberer教授
法国赛诺菲研发联盟管理高级总监, IMI COMPACT Consortium常务董事
|
Muthiah Manoharan博士
美国Alnylam制药公司高级副总裁，新药开发负责人
|
Brett Monia博士
美国Isis 制药公司高级副总裁
Oligonucleotide Therapeutics Society当选主席
|
大会拟定议程
|
Wed, Nov 5, 2014
|
||
|
Registration 13:00-18:00
|
||
|
|
||
|
Thu, Nov 06, 2014 (Day 1)
|
||
|
|
Chair
|
Mano Manoharan, PhD Senior Vice President, Alnylam Pharmaceuticals, USA
|
|
08:30-08:45
|
Introduction
|
CNAF Organizing Committee
|
|
08:45-09:30
|
Opening Keynote
|
Craig Mello, PhD Professor, University of Massachusetts Medical School, HHMI, 2006 Nobel Prize Winner, USA
Title: RNA-guided genome defense and new frontiers in biotech and medicine
|
|
09:30-10:10
|
Keynote
|
Brett Monia, PhD Senior Vice President, Isis Pharmaceuticals, OTS President, USA
Title: Transforming drug discovery for human therapeutics with antisense technology
|
|
10:10-10:35
|
Plenary
|
Judy Lieberman, MD, PhD Professor, Program Chair, Harvard Medical School, USA
Title: Targeted gene knockdown to treat cancer
|
|
10:35-10:55
|
Tea Break
|
|
|
10:55-11:20
|
Plenary
|
Matthew Porteus, MD, PhD Professor, Stanford School of Medicine, CRISPR Therapeutics Founder, USA
Title: Genome editing using engineered nucleases
|
|
11:20-11:45
|
Plenary
|
Erwei Song, MD, PhD Professor and Vice Dean, Sun Yat-Sen Memorial Hospital, China
Title: BRMS1L suppresses breast cancer metastasis by inducing epigenetic silence of FZD10
|
|
11:45-12:00
|
Technology
|
Rick Hogrefe, PhD Founder, President and Chief Executive Officer, TriLink BioTechnologies
Title: Designing a mRNA therapeutic suitable for scale up
|
|
12:00-13:30
|
Lunch
|
|
|
13:30-13:35
|
Chair
|
Brett Monia, PhD Senior Vice President, Isis Pharmaceuticals, OTS President, USA
|
|
13:35-14:15
|
Keynote
|
Troels Koch, PhD Senior Vice President and Chief Technology Officer, Santaris / Roche, Denmark
Title: LNA antisense – concepts & status
|
|
14:15-14:40
|
Plenary
|
Dmitry Samarsky, PhD Executive Vice President, Technology Development, RiboBio, China
Title: In vivo delivery of therapeutic oligonucleotides and potential applications for cancer
|
|
14:40-15:05
|
Plenary
|
Georg Sczakiel, PhD Professor, University of Lübeck, Germany
Title: Target RNA is involved in guide strand loading of Argonaute-2 and siRNA-induced RNA interference
|
|
15:05-15:25
|
Tea Break
|
|
|
15:25-15:50
|
Plenary
|
Peixuan Guo, PhD Professor, William S. Farish Fund Endowed Chair, University of Kentucky, USA
Title: A new generation of drugs from the emerging field of RNA nanotechnology
|
|
15:50-16:15
|
Plenary
|
Yi Jin, PhD Executive Vice President, Suzhou Ribo Life Science, China
Title: RNAi based therapeutics for Hepatitis B
|
|
16:15-16:30
|
Technology
|
Suresh Srivastava, PhD Founder and President, ChemGenes, USA
Title: BMEG oligonucleotides for efficient cellular delivery for therapeutic and molecular biological applications
|
|
16:30-16:55
|
Plenary
|
David Lewis, PhD Chief Scientific Officer, Arrowhead Research Corporation, USA
Title: Using Dynamic Polyconjugate® (DPC) technology to advance RNAi-based therapeutics
|
|
16:55-17:00
|
Day End
|
CNAF Organizing Committee
|
|
Fri, Nov 07, 2014 (Day 2)
|
||
|
09:00-09:05
|
Chair
|
Troels Koch, PhD Senior Vice President and Chief Technology Officer, Santaris / Roche, Denmark
|
|
09:05-09:45
|
Keynote
|
Ekkehard Leberer, PhD Professor, Senior Director of R&D Alliance Management, Sanofi, Germany
Title: Nucleic acid therapeutics: opportunities and challenges for innovation in drug development
|
|
09:45-10:10
|
Plenary
|
William Marshall, PhD President and Chief Executive Officer, Board Director, miRagen Therapeutics, USA
Title: Discovery and development of microRNA targeting therapeutics
|
|
10:10-10:35
|
Plenary
|
Micky Tortorella, PhD Chief Technology Officer and Vice President for Drug Discovery and Technology Transfer, Guangzhou Institutes of Biomedicine and Health, China
Title: Intra-articular delivery of siRNA-conjugates as new disease modifying osteoarthritis drugs
|
|
10:35-10:55
|
Tea Break
|
|
|
10:55-11:20
|
Plenary
|
Chengyu Jiang, PhD Professor, Chair, Peking Union Medical College, CAMS, China
Title: Hsa-miR-1246, hsa-miR-320a and hsa-miR-196b-5p inhibitors can reduce the cytotoxicity of Ebola virus glycoprotein in vitro
|
|
11:20-11:45
|
Plenary
|
Marc Lemaitre, PhD Chief Executive Officer, Sirnaomics, USA / China
Title: Improving siRNA therapeutics using polymer-nanoparticle (PNP) delivery: recent pre-clinical results with STP705 against skin scars
|
|
11:45-12:00
|
Technology
|
Kimo Sanderson Vice President, Asahi Kasei, Japan
Title: Therapeutic oligonucleotides from discovery to development: the importance of proper production and scale up
|
|
12:00-13:30
|
Lunch
|
|
|
13:30-13:35
|
Chair
|
William Marshall, PhD President, Chief Executive Officer, Board Director, miRagen Therapeutics, USA
|
|
13:35-14:15
|
Keynote
|
Mano Manoharan, PhD Senior Vice President, Alnylam Pharmaceuticals, USA
Title: Chemical strategies for systemic delivery of RNAi drugs
|
|
14:15-14:40
|
Plenary
|
Dirk Haussecker, PhD Founder and Curator, RNAi Therapeutics Blog, Germany
Title: RNA therapeutics emerging as major drug discovery engine
|
|
14:40-15:05
|
Plenary
|
TBD
|
|
15:05-15:20
|
Technology
|
Carina Andersson, PhD Marketing Head, GE, USA
Title: A manufacturing solution of oligonucleotides
|
|
15:20-15:40
|
Tea Break
|
|
|
15:40-16:05
|
Plenary
|
Sven Klussmann, PhD Chief Scientific Officer, NOXXON Pharma, Germany
Title: From bench to bedside – the conversion of mirror-image oligonucleotides into therapeutics
|
|
16:05-16:30
|
Plenary
|
Ryszard Kole, PhD Distinguished Scientist, Professor, Sarepta Therapeutics, USA
Title: Eteplirsen, a phosphorodiamidate morpholino oligonucleotide, as treatment for Duchenne muscular dystrophy (DMD)
|
|
16:30-16:55
|
Plenary
|
René Thürmer, PhD Deputy Head of the Unit Pharmaceutical Biotechnology, BfArM - Federal Institute for Drugs and Medical Devices, Germany
Title: Regulatory aspects of nucleic acids therapeutics
|
|
16:55-17:15
|
Closing Remarks
|
Craig Mello, PhD Professor, University of Massachusetts Medical School, HHMI, 2006 Nobel Prize Winner, USA
|
会议时间：2014年11月5-7日
会议地点：广州科学城翡翠皇冠假日酒店
会议语言：英语
论坛网站：www.cnaf.org.cn（点此注册）
赞助企业：
白金赞助
金牌赞助
银牌赞助
|
|
|
|
|
铜牌赞助
专项赞助
联系我们：
|
赞助咨询： |
注册及其他咨询： |
- 2026第17届生物发酵产品与技术装备展即将开幕
- 2027上海绿色智造与节能技术（过滤与分离）展通知
- 康森特诚邀您共赴岳麓大会暨湖南未来产业发展大会
- 盛嘉颐邀您共赴第七届北京单细胞与空间组学论坛
- 西美杰邀您莅临2026 CSGCT大会 A36 展位
- 谱镭光电携德国Gitterwerk透射光栅亮相深圳光博会
- 2026CIOE中国光博会落幕，滨松四大展区亮点回顾
- AsiaBIO创新峰会（华南站）嘉宾首发
- 谱镭光电携Vialux数字微镜系统DMD亮相深圳光博会
- 展会预告：曼博生物将携小核酸研发工具亮相SNA2026
- 2026广州检博会12月启幕，聚力赋能质量产业升级
- 奥伟登携神经科学多尺度显微成像方案亮相CNS 2026
- BCIC 2026脑机接口技术创新与产业发展大会通知
- 2027第34届河北医疗设备与健康产业展览会邀请函
- 东乐成功参展中国神经科学学会第十九届全国学术会议
- "数"你好运，乐备实0元免费体验多因子检测(第17期)
- 乐备实PLA空间原位蛋白互作福利，满额即赠实验耗材
- 乐备实开学季狂欢价特惠,多因子检测服务现货2周交付
- 伯豪生物2026国自然金榜赋能科研计划正式启动
- 乐备实PLA空间原位蛋白互作服务热门固定套餐促销
- 优宁维人源12色T细胞耗竭标准化流式Panel全新上线
- 丹望医疗星火计划启航:免费赠类器官,助力构建数据库
- 乐备实细胞因子免费测，0元免费体验多因子检测
- 乐备实肿瘤免疫检查点14因子Panel上新限时优惠
- 乐备实炎症免疫固定整板因子检测送生信云平台免费用
- 乐备实LabEx细胞因子自选检测库上线,14因子自由组合
- 乐备实惊喜618大促，血清、血浆等体液样本满10拼板
- SBC正式启动新一轮器官芯片合作共研项目招募计划
- 10x Visium HD平台升级：11mm大面积捕获区域上线
- 法赞雷生：国产失眠创新药获批，双重机制带来新选择
